Entry Point Capital, LLC Akebia Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
120Shares Held
54.9MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$26.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$22.9 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$13 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$10.8 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$8.44 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $417M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...